MRNA Kills Covid... Can It Also Kill Cancer?

MRNA is about to save a lot more lives. MRNA is about to save a lot more lives. Energy and Capital: Practical Investment Analysis in the new Energy Economy [Energy and Capital logo] MRNA Kills Covid... Can It Also Kill Cancer? By Keith Kohl | October 21, 2021 - Baltimore, MD Hi, Keith Kohl here. MRNA is about to save a lot more lives. As I’m sure you’ve likely read in the news, mRNA is the breakthrough tech behind the Pfizer and Moderna vaccines for COVID-19... But this is only the beginning of what’s possible. According to the world’s top scientists, mRNA has the power to do so much more. It can even fight cancer! By teaching our immune systems how to target cancer cells, a sick person could recover without other invasive treatments. FDA trials are already underway. Trial patients are already reporting results. MRNA has the potential to save the lives of thousands of people suffering from these horrible diseases. It can also be used to protect healthy people as well. You see, unlike current medicines, in many cases mRNA can be used to attack diseases before they become a problem. At-risk people could use the mRNA medicine to fight off cancer cells before they even have a chance to spread. Biotech labs are getting aggressive — and they’re taking on the world’s worst diseases. There will soon be mRNA vaccine trials for: - Autoimmune disorders - Cystic fibrosis - Lyme disease - SARS and other respiratory viruses - And many more So why is this all happening so fast? It’s thanks to the billions of dollars mRNA research received during the pandemic. Biotech labs have logged a record-breaking year, creating more medicines than ever before. It’s an exciting time in medicine... And it’s also unleashing a flood of profits for biotech investors. When Moderna first began research on mRNA technology, nobody had heard of the company. But the moment it developed its COVID vaccine, it went from total obscurity to a household name, all in just a few months. And its stock soared with its success — from $18 to over $400 a share. That’s a 2,122% gain — in just 21 months! Enough to turn a $5,000 investment into more than six figures! Thousands of investors were able to become millionaires from this one stock. But the vaccine drive isn't over — not by a long shot. There are going to be even more COVID vaccines. With new COVID variants like delta popping up around the country, new medicines are in development. We’re in the earliest days of what’s possible — especially from the biotech firms on the cutting edge. We’re seeing bigger innovations (and bigger stock gains!) than we ever have before. I’ve found a small group of biotech firms that are releasing FDA trial results in the next 45 days... And they have the potential to go far. Let me show you why [we’re about to see a flood of biotech profits in the weeks ahead.]( To your wealth, [Keith Kohl sig] Keith KohlInvestment Director, Topline Trader P.S. This is how the next mRNA millionaires will be made — I urge you to read my urgent update on why [these small biotech firms]( are leading the way. --------------------------------------------------------------- This email was sent to {EMAIL}. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here](, and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Energy and Capital, please add newsletter@energyandcapital.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. Energy and Capital, Copyright © 2021, Angel Publishing LLC. All rights reserved. 3 E Read Street, Baltimore, MD 21202. Your privacy is important to us – we will never rent or sell your e-mail or personal information. Please read our [Privacy Policy](. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment advice. Read our [Details and Disclosures.](